ONCOMED PHARMACEUTICALS INC's ticker is OMED and the CUSIP is 68234X102. A total of 59 filers reported holding ONCOMED PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $5,000 | -64.3% | 1,500 | 0.0% | 0.00% | – |
| Q1 2017 | $14,000 | +16.7% | 1,500 | 0.0% | 0.00% | – |
| Q4 2016 | $12,000 | -29.4% | 1,500 | 0.0% | 0.00% | – |
| Q3 2016 | $17,000 | -5.6% | 1,500 | 0.0% | 0.00% | -100.0% |
| Q2 2016 | $18,000 | +20.0% | 1,500 | 0.0% | 0.00% | – |
| Q1 2016 | $15,000 | -55.9% | 1,500 | 0.0% | 0.00% | -100.0% |
| Q4 2015 | $34,000 | +36.0% | 1,500 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $25,000 | -26.5% | 1,500 | 0.0% | 0.00% | 0.0% |
| Q2 2015 | $34,000 | -12.8% | 1,500 | 0.0% | 0.00% | 0.0% |
| Q1 2015 | $39,000 | +18.2% | 1,500 | 0.0% | 0.00% | -50.0% |
| Q4 2014 | $33,000 | +17.9% | 1,500 | 0.0% | 0.00% | +100.0% |
| Q3 2014 | $28,000 | -20.0% | 1,500 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $35,000 | -30.0% | 1,500 | 0.0% | 0.00% | -50.0% |
| Q1 2014 | $50,000 | +13.6% | 1,500 | 0.0% | 0.00% | 0.0% |
| Q4 2013 | $44,000 | – | 1,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,108,815 | $4,273,000 | 0.48% |
| Birchview Capital, LP | 372,557 | $387,000 | 0.24% |
| Perceptive Advisors | 1,719,111 | $1,787,000 | 0.05% |
| Fondren Management LP | 25,136 | $26,000 | 0.02% |
| Cannell & Co. | 281,983 | $293,000 | 0.01% |
| APPLETON PARTNERS INC/MA | 66,206 | $69,000 | 0.01% |
| Quinn Opportunity Partners LLC | 66,162 | $69,000 | 0.01% |
| NJ State Employees Deferred Compensation Plan | 38,000 | $40,000 | 0.01% |
| Candriam S.C.A. | 380,000 | $395,000 | 0.01% |
| PRIMECAP MANAGEMENT CO/CA/ | 5,451,400 | $5,669,000 | 0.00% |